Advanced Hybrid Closed Loop System (780G) for People With Type 1 Diabetes Mellitus Patients Over the Age of 60: Efficacy in Improving Glucose Indices, Quality of Life, Cognitive Functions and Physical Capacity
The trial is a randomized controlled, parallel group design study. Patients will be followed up during approximatively 12 months. Patients will be randomized to either the MDI/CSII group which will continue their treatment as per routine procedures and the advanced Hybrid Closed Loop system (AHCL) group which will be connected to the Minimed 780G system. . At the end of the 12 month study period, we will evaluate whether the AHCL system improved glucose indices in older individuals with Type 1 diabetes mellitus (T1DM) and assess whether the ACHL treatment improved physical capacity, frailty \& sarcopenia indices as well as quality of life and cognitive functions.
• Age over 60 years
• T1DM
• Willing to participate in a study for the specified duration
• Willing to perform ≥ 4 finger stick blood glucose measurements daily or connected to a basket approved CGM
• Willing to wear the system continuously throughout the study
• Treated with MDI/CSII (with exclusion of 780G or other hybrid closed systems)
• Lack of advanced complications of diabetes